Every 8-K that CalciMedica, Inc. (CALC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. (CALC) reports an update on its Nasdaq listing status. After previously falling below Nasdaq’s $35,000,000 market value of listed securities requirement, Nasdaq has now determined that CalciMedica satisfies the alternative stockholders’ equity standard under Listing Rule 5550(b)(1), based on reported equity of $5,513,000 as of June 30, 2026. This closes the prior deficiency related to market value of listed securities.
The company remains out of compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement under Listing Rule 5550(a)(2). CalciMedica has until September 14, 2026 to regain compliance. A one-for-five reverse stock split of its common stock became effective at 5:00 p.m. Eastern Time on August 28, 2026, but there is no assurance the company will meet the minimum bid price or maintain overall listing compliance.
CalciMedica, Inc. (CALC) approved and is implementing a 1-for-5 reverse stock split of its outstanding common stock and a reduction of authorized common shares from 500,000,000 to 100,000,000 through a Certificate of Amendment filed in Delaware.
The amendment becomes effective at 5:00 p.m. Eastern Time on August 28, 2026. Every five issued and outstanding common shares will be combined into one share, with no change in par value. Equity awards, warrants and plan reserves will be adjusted proportionately, and holders otherwise entitled to fractional shares will receive cash instead. CALC shares will begin trading on a split-adjusted basis on August 31, 2026 on The Nasdaq Capital Market under the same ticker.
CalciMedica, Inc. (CALC) reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing shares of common stock authorized for issuance under the plan by 7,500,000 and revising how the annual automatic share reserve increase is calculated.
Stockholders elected two Class III directors to terms through the 2029 annual meeting, ratified Baker Tilly US, LLP as independent auditor for 2026, and approved, on an advisory basis, executive compensation and an annual say‑on‑pay frequency. They also approved an amendment to the certificate of incorporation to permit a reverse stock split in a range of 1‑for‑2 to 1‑for‑10, with a proportional reduction in authorized common shares, to be implemented at the Board’s discretion.
In addition, stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of Series A and Series B common stock warrants and related shares under a June 23, 2026 Securities Purchase Agreement, and, under Rule 5635(c), similar warrant issuances to certain directors and officers.
CalciMedica, Inc. reported second quarter 2026 results and outlined pipeline and financing updates. A private placement of up to approximately $49 million, including approximately $15 million upfront, is intended to advance its pulmonary hypertension strategy around Auxora and oral candidate CM5480. The company plans a Phase 1b proof‑of‑concept trial of Auxora in pulmonary arterial hypertension with data anticipated in mid‑2027, and expects an IND submission for CM5480 in mid‑2027. In acute pancreatitis, the FDA aligned on the Phase 2b trial design with a primary endpoint focused on reducing new‑onset severe respiratory failure, though trial initiation depends on additional financing. Cash and cash equivalents were $18.6 million as of June 30, 2026, and the company expects its cash to fund operations into the second half of 2027. For the quarter, net loss was $7.7 million (or $0.45 per share), compared with a net loss of $6.0 million (or $0.40 per share) a year earlier, while operating expenses declined due to lower R&D and G&A spending.
CalciMedica, Inc. reported changes to its board of directors. On July 2, 2026, the board expanded from seven to eight members and appointed Evgeny Zaytsev, M.D., Ph.D. as a Class I director, with a term running until the 2027 annual meeting of stockholders.
Under the company’s non-employee director compensation policy, he will receive a pro-rated annual cash retainer of $40,000 and an option to purchase 20,000 shares of common stock, vesting monthly over three years from July 2, 2026, subject to continuous service. CalciMedica also disclosed that director Fred Middleton intends to retire effective at the 2026 annual meeting, at which time the board size will return to seven, and that his retirement does not stem from any disagreement with the company.
CalciMedica, Inc. entered a securities purchase agreement for a private placement of 18,673,429 units, providing approximately $15 million in upfront gross proceeds and up to about $49 million in total potential gross proceeds including Series A and Series B warrant exercises.
Each unit includes common stock or a pre-funded warrant plus rights to Series A and B warrants, with exercise prices of $0.8033 and $1.00 per share, respectively. The company plans to use the funds to advance a pulmonary hypertension program, including a Phase 1b Auxora proof-of-concept study in PAH and IND-enabling work for oral candidate CM5480.
The company estimates that net proceeds, together with existing cash, will fund operations into the second half of 2027. CalciMedica also reported that the FDA reviewed a protocol amendment and interim safety data for the Phase 2 KOURAGE trial of Auxora in acute kidney injury and provided no comments, allowing dosing in the study to continue.
CalciMedica, Inc. amended its loan and warrant arrangements with Avenue funds, extending debt maturity and adding equity-linked features. The company’s $10,000,000 loan now has an interest-only period through September 30, 2027 and a new maturity date of September 1, 2029, in exchange for a $200,000 increase in the final payment fee.
The lender’s conversion right was expanded to allow conversion of up to $3,000,000 of loan principal into common stock or pre-funded warrants at a $1.00 stock purchase price, subject to volume and price conditions and beneficial ownership limits. CalciMedica also reduced the exercise price of an existing warrant on 641,163 shares to $1.00 and issued a new warrant for 1,000,000 shares at $1.00, both with a beneficial ownership cap not to exceed 19.99%. The new warrant is exercisable until June 23, 2031 and, along with the conversion and related securities, was issued in a private transaction relying on a Section 4(a)(2) exemption.
CalciMedica reported a profitable first quarter of 2026 and highlighted progress across its pipeline. Net income was $5.0 million for the quarter ended March 31, 2026, or $0.31 per basic share and $0.30 per diluted share, compared with a $5.0 million net loss a year earlier. Other income rose to $10.6 million, mainly from fair value adjustments to a promissory note and common stock warrants, while research and development and general and administrative expenses both declined year over year.
Cash and cash equivalents were $8.2 million as of March 31, 2026, and the company expects this to fund its current operating plan into the fourth quarter of 2026. CalciMedica expects FDA feedback in the second quarter of 2026 on the design of a potential pivotal Auxora program in acute pancreatitis and on potential future development in acute kidney injury, and it is advancing its oral CRAC inhibitor CM5480 toward an anticipated IND submission in pulmonary hypertension in 2027.
CalciMedica, Inc. reported that Nasdaq has notified the company it no longer meets multiple continued listing standards for the Nasdaq Capital Market. The market value of its listed securities has stayed below the $35,000,000 minimum for 30 consecutive business days, triggering a 180-day cure period ending on September 9, 2026.
The company can regain compliance by meeting any of the alternatives: stockholders’ equity of at least $2,500,000, market value of listed securities of at least $35,000,000, or net income from continuing operations of $500,000 in the relevant periods. Separately, Nasdaq also notified CalciMedica that its common stock has traded below the $1.00 minimum bid price for 30 consecutive business days, starting another 180-day grace period through September 14, 2026 to restore the bid price for at least 10 consecutive business days.
The stock continues to trade on Nasdaq under the symbol CALC, but failure to regain compliance could lead to delisting. The company plans to monitor the requirements and is considering options such as a reverse stock split, while noting there is no assurance it will successfully regain or maintain compliance.
CalciMedica Inc. reported a full-year 2025 net loss of $29.6 million, or $1.97 per share, compared with a net loss of $13.7 million in 2024. Research and development spending rose to $15.2 million, while general and administrative expenses fell to $7.9 million.
Cash, cash equivalents and short-term investments totaled $13.0 million as of December 31, 2025, which the company expects will fund its current operating plan into the fourth quarter of 2026. Liabilities increased, including a promissory note and a higher warrant liability, leading to a stockholders’ deficit.
Clinically, the company reported no evidence of drug-related toxicity from the unblinded Phase 2 KOURAGE AKI trial, despite a previously disclosed mortality imbalance and trial discontinuation. Auxora is being advanced toward a pivotal acute pancreatitis program, with design expected to be finalized in the first half of 2026, and CM5480 continues preclinical development for pulmonary arterial hypertension with an IND submission anticipated in 2027.
CalciMedica, Inc. reported that it has discontinued its Phase 2 KOURAGE clinical trial after a recommendation from the study’s Independent Data Monitoring Committee. The company cited reduced planned operating expenses from stopping the trial and updated its cash outlook accordingly.
CalciMedica now expects its existing cash, cash equivalents and short-term investments to fund its current operating plan into the fourth quarter of 2026, an improvement from its prior guidance of funding into the second half of 2026. The company also reiterated standard cautionary language about forward-looking statements and referenced previously disclosed risk factors.
CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure. The move follows a safety-related recommendation from the trial’s Independent Data Monitoring Committee, which believes the study design and patient enrollment criteria should be reevaluated.
The company states there were no deaths assessed as related to Auxora or placebo, and no serious adverse events triggered expedited U.S. Food and Drug Administration reporting. CalciMedica will conduct a comprehensive review of the unblinded data to understand how baseline characteristics, disease severity and concomitant therapies influenced outcomes and to determine how future clinical evaluation of Auxora in AKI may proceed. The FDA has been notified, and investigators will follow all enrolled patients for 90 days.
CalciMedica, Inc. (CALC) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed under the Exchange Act and is not subject to Section 18 liabilities. It will not be incorporated by reference into other filings except if specifically referenced.
CalciMedica, Inc. (CALC) increased its at‑the‑market capacity to $9,700,000. The company filed a prospectus supplement to raise the maximum aggregate offering price of common stock that may be issued under its at‑the‑market offering agreement with H.C. Wainwright & Co.
The prior limit under the program was $4,450,000, as referenced in an earlier supplement. A legal opinion covering the $9,700,000 of common stock was included as Exhibit 5.1.
CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.
The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.
CalciMedica (NASDAQ: CALC) filed an 8-K summarizing the 2025 Annual Meeting held on 24 Jun 2025.
- Equity Incentive Plan amended: share reserve increased by 600,000 shares (≈4.3 % of the 13.97 M shares outstanding).
- Three Class II directors—Rachel Leheny, Eric Roberts, Frederic Guerard—re-elected for terms ending 2028.
- Baker Tilly US ratified as independent auditor for FY 2025.
The amendment enhances retention tools but introduces incremental dilution; no additional financial data or strategic shifts were disclosed.